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β‑amyloid is an important factor in the pathophysiology of Alzheimer’s disease.This study investigates β‑amyloid’s role in the regulation 
of nociception in mice. Pretreated once, 2 weeks prior to testing with β‑amyloid, male ICR mice were examined on various nociceptive 
tests. Pretreatment with β‑amyloid reversed the nociceptive effects induced by intraperitoneally administered acetic acid (writhing 
response) and intraplantar injection of 5% formalin into the hind paw. β‑amyloid pretreatment also elevated the threshold for 
nociception in the mechanical von Frey test. Additionally, p‑CREB and p‑ERK levels in the spinal cord and the adrenal gland increased 
after formalin injection. Pretreatment with β‑amyloid attenuated formalin‑induced overexpression of p‑CREB and p‑ERK in the spinal 
cord and the adrenal gland. Our results suggest that chemical and mechanical nociception appear to be altered in β‑amyloid‑treated 
animals. Furthermore, the reduction of nociception by β‑amyloid in the formalin pain model appears to be mediated, at least in part, by 
the suppression of p‑CREB and p‑ERK level in the spinal cord and the adrenal gland.
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INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative 
disorder characterized by dementia, cognitive im‑
pairment, and memory loss. β‑amyloid is one of the 
pathological mediators leading to AD (Sisodia and 
Price, 1992). A major neuropathological component 
of AD progression is deposition of β‑amyloid, which is 
derived from larger amyloid precursor proteins. Post‑
mortem brains of AD patients reveal neuropathological 
features including the presence of β‑amyloid plaques 
and neurofibrillary tangles, which also contain β‑amy‑
loid peptide (Sojkova and Resnick, 2011).
Several lines of clinical evidence have demon‑
strated nociceptive changes in patients with AD. For 
example, Benedetti et al. (1999) reported that pain 
tolerance was increased in Alzheimer’s patients. How‑
ever, the relationship between AD pathology and pain 
perception is still rather unclear (Monroe et al., 2012). 
An earlier study demonstrated that β‑amyloid acts 
as a blocking mediator in amyloid precursor protein 
(APP) over‑expressing CRND8 transgenic mice (Shukla 
et al., 2013), suggesting that β‑amyloid may be respon‑
sible for blunted pain perception observed in Alzhei‑
mer’s patients.
Recent studies have shown that the extracellular 
signal‑regulated kinase P44/42 (ERK1/2) and cyclic 
AMP response element‑binding protein (CREB) are 
involved in various types of pain transmission. Both 
CREB and ERK protein expression are elevated in dorsal 
root ganglia (DRG) and spinal cord in rat neuropathic 
pain models (Crown et al., 2006; Ji et al., 2009). For ex‑
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ample, the expression of spinal ERK and CREB proteins 
are correlated with the development allodynia after 
spinal cord injury (Crown et al., 2006). ERK protein also 
contributes to pain sensitization after tissue and nerve 
injury (Ji et al., 2009), as well as in the production of 
neuropathic pain (Han et al., 2011). Additionally, both 
CREB and ERK protein expression are also elevated in 
a diabetic neuropathy model and in a capsaicin‑treat‑
ed pain model (Miyabe and Miletic, 2005; Song et al., 
2005; Wu et al., 2005; Dang et al., 2014). However, the 
role of spinal CREB and ERK proteins in the modulation 
of nociception in β‑amyloid‑pretreated animal models 
has not yet been explored.
Although previous studies have suggested that 
pain perception is altered in Alzheimer’s patients, the 
exact role and mechanism of β‑amyloid in the brain 
in the regulation of nociception has not been thor‑
oughly characterized. Thus, the present study was 
designed to examine the effect of supraspinal β‑amy‑
loid pretreatment on nociceptive behavior in several 
mouse pain models. Furthermore, the potential roles 




Male ICR mice (6 weeks of age) weighing 25‑30 g at 
the beginning of experiments (Myung‑Jin, Inc., Seoul, 
Korea) were used in the experiments. The mice were 
housed 5 per cage in a room maintained at 22±1°C with 
an alternating 12‑hour light‑dark cycle. Food and water 
were available ad libitum. The animals were allowed to 
adapt to the laboratory for at least 2 h before testing 
and were only used once. To reduce variation, all ex‑
periments were performed during the light phase of 
the cycle (10:00~17:00).
Drug
β‑amyloid from Sigma‑Aldrich (St. Louis, MO, USA) 
was dissolved in saline (0.9% NaCl). The β‑amyloid 
(410 pmol/mice) was administered i.c.v. as described 
previously (Song et al., 1998; Yan et al., 2001; Cho et al., 
2005). β‑amyloid was prepared just prior to using.
Experimental design
To examine the change of pain perception after 
β‑amyloid injection, mice were performed in three dif‑
ferent nociceptive models: visceral pain model, forma‑
lin pain model, and von Frey test. In the behavior test, 
the mice were divided randomly into two groups: the 
normal mice group (control group) and the β‑amyloid 
injected group.
The i.c.v. administration of β‑amyloid (410 pmol/ 
5 μl) was performed following the procedure estab‑
lished by Laursen and Belknap (1986). Briefly, each 
mouse was injected at bregma with a 50 μl Hamilton 
micro syringe fitted with a 26‑gauge needle that was 
inserted to a depth of 2.4 mm. The i.c.v. injection vol‑
umes were 5 µl, and the injection sites were verified by 
injecting a similar volume of 1% methylene blue solu‑
tion and determining the distribution of the injected 
dye in the ventricular space. The experiments were 
performed only when the success rate of i.c.v. injection 
was over 95%.
We next measured whether the expression level 
of signal molecular proteins is altered in the spinal 
cord and the adrenal gland after β‑amyloid injection. 
Mice were randomly divided into four groups. Control 
group: the normal mice. β‑amyloid group: these mice 
were tested after 2 weeks of i.c.v. pretreatment with 
β‑amyloid. Saline + 5% formalin group: mice were i.c.v. 
pretreatment with 5 μl saline, after 2 weeks mice were 
injected 5% formalin in the left hind paw. β‑amyloid + 
5% formalin group: mice were i.c.v. pretreatment with 
β‑amyloid (410 pmol), after 2 weeks mice were injected 
5% formalin in the left hind paw.
Nociceptive models and nociceptive  
behavior measurements
These nociceptive behavior tests were performed 
after 2 weeks of the pretreatment of β‑amyloid. For 
the visceral pain model (Feng et al., 2019), 1% ace‑
tic acid was injected intraperitoneally (10 mL/kg of 
body weight). The number of writhing responses (as 
a measure of visceral pain) was counted for 30 min 
after acetic acid injection. For the formalin pain 
model (Hunskaar et al., 1985), 10 μl of 5% formalin 
was injected subcutaneously under the plantar sur‑
face of the left hind paw. Nociceptive behaviors such 
as shaking and licking the hind paws were count‑
ed during the first phase (0‑5 min) and the second 
phase (20‑40 min) using a stop watch. Mechanical 
allodynia was assessed by von Frey testing (Bonin et 
al., 2014). For the von Frey test, mice were individ‑
ually placed in a clear glass cell with a metal mesh 
floor, allowed to adapt to the testing environment 
for 30 min, and then von Frey filaments (North Coast 
Medical, Inc., Gilroy, CA, USA) were applied to the 
plantar surface using an up and down paradigm. 
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Then the mice hind paw withdrawal threshold was 
compared. In these behavior experiments, 8 animals 
were used per group.
Western blot
The mouse adrenal gland and spinal cord were 
dissected at 20 min after 5% formalin injection. Tis‑
sue was washed twice with cold Tris‑buffered sa‑
line (20 mmol/L Trizma base and 137 mmol/L NaCl, 
pH 7.5). Immediately after washing, tissues were lysed 
with sodium dodecyl sulfate lysis buffer (62.5 mmol/L 
Trizma base, 2% w/v sodium dodecyl sulfate, 10% 
glycerol) containing 0.1 mmol/L Na3VO4, 3 mg/mL 
aprotinin, and 20 mmol/L NaF. After brief sonica‑
tion, the concentration of protein was determined 
with a detergent‑compatible protein assay reagent 
(Bio‑Rad Laboratories, Hercules, CA, USA) using bo‑
vine serum albumin as the standard. After adding bro‑
mophenol blue (0.1% w/v), the proteins were boiled, 
separated by electrophoresis in 10‑12% polyacryl‑
amide gels, and transferred onto a polyvinylidene 
difluoride membrane (Millipore, Bedford, MA, USA). 
The membranes were immunoblotted with antibod‑
ies p‑ERK1/2 (Abcam, USA; 1:1000), p‑CREB (Abcam, 
USA; 1:1000) and β‑actin (Cell Signaling Technolo‑
gy, USA; 1:1000) in a blocking buffer for 1 h at room 
temperature. Membranes were then washed 4 times 
with Tris‑buffered saline containing 20% Tween‑20 
(TBST; 10 mM Trizma base (pH 8.0), 150 mM NaCl, and 
20% Tween 20) for 20 min and then incubated with 
the anti‑rabbit IgG‑horseradish peroxidase conju‑
gate (1:5000) in blocking buffer at room temperature 
for 1 h. After washing the membranes with TBST for 
20 min (4 times), ECL‑plus solution (Millipore, Biller‑
ica, MA, USA) was added. Then the membranes were 
exposed to Hyperfilm‑MP (Amersham Phamacia Bio‑
tech) for detection of light emission. The specific sig‑
nals were quantified with the Multi‑Gauge Version 3.1 
(Fuji Film, Japan) and expressed as the percentage of 
the control (Sim et al., 2014; Kang et al., 2015).
Statistics
All values were expressed as the mean ± stan‑
dard deviation (SEM). The statistical significance of 
differences among multiple variables were assessed 
with two‑way ANOVA with Tukey’s post hoc test using 
GraphPad Prism (Version 8.0.2, GraphPad Software, 
USA). Differences between the groups were assessed 
using unpaired t‑tests. Statistical significance was in‑
dicated by p‑values less than 0.05.
RESULTS
Changes in nociceptive behaviors  
in the β‑amyloid‑pretreated group  
in various pain models
ICR mice were pretreated once, 2 weeks prior to 
testing with 410 pmol of β‑amyloid. In the writhing 
test, 1% acetic acid was administered i.p. and the 
number of writhing events was counted for 30 min. As 
shown in Fig. 1A, the i.c.v. pretreatment with β‑am‑
yloid attenuated the number of writhing events in‑
duced by acetic acid, compared to the control group 
(t8=9.439, P<0.0001). In the formalin test, 5% formalin 
was injected into the hind‑paw. As shown in Fig. 1B, 
compared to the control group, the i.c.v. pretreat‑
ment with β‑amyloid attenuated the nociceptive 
behaviors during both 1st and 2nd phases (t8=8.498, 
P<0.0001; t8=12.31, P<0.0001, respectively). As shown 
in Fig. 1C, β‑amyloid pretreatment for 2 weeks caused 
an elevation in the mechanical stimulation threshold 
as measured by the von Frey test (t8=2.637, P=0.0298), 
compared to the control group.
Changes in phosphorylated CREB and ERK 
proteins in the spinal cord and adrenal 
gland after β‑amyloid pretreatment in 
a formalin‑induced pain model
The lumbar spinal cord and adrenal gland were 
dissected 20 min after 5% formalin was injected 
into hind paws, and protein was extracted for West‑
ern blot analysis. As shown in Fig. 2A, B, formalin 
injection caused an elevation of p‑CREB (F1,5=298.3, 
P<0.001) and p‑ERK (F1,5=305.0, P<0.001) protein levels 
in the spinal cord, compared to the control group. 
However, two‑way ANOVA (formalin × β‑amyloid) 
revealed that i.c.v. pretreatment with β‑amyloid 
caused reductions in formalin‑induced elevations 
of p‑CREB (F1,5=206.5, P<0.001) and p‑ERK (F1,5=237.8, 
P<0.001) protein levels in the spinal cord, compared 
to the saline + 5% formalin group (Fig. 2A, B). Addi‑
tionally, in Fig. 2C, D, compared to the control group, 
p‑CREB (F1,5=89.48, P<0.001) and p‑ERK (F1,5=13.26, 
P<0.05) protein levels in the adrenal gland were also 
altered by formalin. A two‑way ANOVA (formalin × 
β‑amyloid) showed that β‑amyloid produced a sig‑
nificant effect of the expression level of p‑CREB 
(F1,5=148.1, P<0.001) and p‑ERK (F1,5=258.3, P<0.001) 
proteins, this indicated that i.c.v. pretreatment with 
β‑amyloid suppressed the elevation of p‑CREB and 
p‑ERK protein levels induced by formalin in the ad‑
renal gland (Fig. 2C, D).
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DISCUSSION
We found that supraspinal pretreatment with 
β‑amyloid caused a reduction in nociceptive behav‑
iors, manifested in writhing‑ and formalin‑pain mod‑
els. In addition, the threshold for mechanical pain 
was elevated in the β‑amyloid‑treated group, sug‑
gesting that β‑amyloid may play an important modu‑
latory role in the regulation of nociception in β‑am‑
yloid‑induced AD. In support of our present finding, 
Shukla et al. (2013) recently reported that β‑amyloid 
acts as a blocking mediator for pain perception in APP 
over‑expressing CRND8 transgenic mice. Likewise, 
Pamplona et al. (2010) reported that i.c.v.‑injected, 
β‑amyloid‑treated mice exhibited an increased jump 
threshold in the foot shock‑sensitivity test. Although 
the results from several clinical studies (Husebo et al. 
2016; Cao et al. 2019) have revealed that nociception 
in Alzheimer’s patients is complex, our study sug‑
gests that the exact role of β‑amyloid in the regula‑
tion of nociception, especially in β‑amyloid‑induced 
Alzheimer’s patients, should be clarified through yet 
further clinical investigation. While we investigated 
the β‑amyloid‑induced AD model, the results from 
this study are partially supported by findings in oth‑
er AD models. For example, colchicine, okadaic acid, 
and streptozotocin (STZ) are also used to induce AD 
(Shree et al., 2017; Malekzadeh et al., 2017). 
Several lines of evidence have previously demon‑
strated that CREB and ERK proteins are closely associ‑
ated with pain transmission. For example, both p‑CREB 
and p‑ERK expression in the spinal cord or dorsal root 
ganglia are up‑regulated in various types of chronic 
pain models, such as neuropathic pain and neuropathy 
(Miyabe and Miletic, 2005; Song et al., 2005). Further‑
more, p‑CREB and p‑ERK expression in the spinal cord 
or brain are up‑regulated in acute inflammatory pain 
models, such as the formalin pain model (Hermanson 
and Blomqvist, 1997; Seo et al., 2008; Hagiwara et al., 
2009; Mao et al., 2013; Kang et al., 2015). Up‑regulation 
of both p‑CREB and p‑ERK expression in a formalin‑in‑
duced pain model was observed in this study. Further‑
more, we found that supraspinal pretreatment with 
β‑amyloid almost completely abolished the p‑CREB 
and p‑ERK expression induced by formalin injection, 
suggesting that the reduction of nociception by β‑am‑
yloid treatment in a formalin pain model appears to be 
mediated, at least in part, by the reduction of p‑CREB 
and p‑ERK level in the spinal cord. Although the exper‑
iment was not carried out, we speculate that β‑amyloid 
located at the supraspinal level may further enhance 
the descending pain inhibitory system, which could 
lead to decreased p‑CREB and p‑ERK expression in the 
spinal cord.
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Fig.  1. β‑amyloid‑induced nociceptive behavioral changes in various 
pain models. ICR mice were β‑amyloid‑pretreated (i.c.v.) once 2 weeks 
before testing. Then, nociceptive behaviors induced by (A) 1% acetic 
acid (i.p.), (B) 5% formalin (intraplantar injection into the hind‑paws), or 
(C) mechanical pain stimulation by von Frey filaments were assessed. 
(A) The number of writhing responses was counted for 30  min after 
acetic acid injection. (B) In the formalin pain test, nociceptive behaviors 
such as vigorous licking and paw shaking were counted during the first 
(0‑5 min) and the second (20‑40 min) phase using a stop watch. (C) The 
mechanical pain threshold was measured by von Frey test. Vertical bars 
indicate the mean ± SEM. Differences between the two means were 
assessed by unpaired t‑test. The number of mice per group was 8. 
*** P<0.001, * P<0.05.
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Our group and others have previously reported that 
the adrenal gland is closely involved with regulation of 
nociception and antinociception (Sim et al., 2013; Kang 
et al., 2014). An earlier study demonstrated that both 
CREB and ERK proteins are involved the regulation of 
adrenal steroidogenesis (Chen et al., 2005). In addition 
to the spinal cord, we found that p‑CREB and p‑ERK 
expression in the adrenal gland are up‑regulated in the 
formalin pain model. Furthermore, increased blood 
glucocorticoid levels are an important aspect of blood 
glucose up‑regulation in several pain models (Sim et 
al., 2013). Thus, it is possible that the up‑regulation of 
CREB and ERK phosphorylation, induced by formalin 
injection, may be related to elevations in blood gluco‑
corticoid levels, which may exert a negative feedback 
influence to alleviate the nociceptive behavior.
CONCLUSION
Taken together, our results describe a decrease in 
chemically‑ or mechanically‑induced nociceptive be‑
haviors in β‑amyloid‑treated mice, suggesting that 
the pain transmission system can be modulated in 
a β‑amyloid‑induced AD animal model. Additionally, 
we observed down‑regulation of p‑CREB and p‑ERK, 
which may be involved in the reduction of nocicep‑
tion by β‑amyloid in the formalin pain model. 
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Fig.  2. Effects of β‑amyloid pretreatment on p‑CREB and p‑ERK expression in the spinal cord and the adrenal gland. ICR mice were 
β‑amyloid‑pretreated  once 2 weeks before testing. Then, the lumbar region of the spinal cord and adrenal gland were dissected. p‑CREB and 
p‑ERK expression in the spinal cord (A and B, respectively) and the adrenal gland (C and D, respectively) were analyzed by Western blot. β‑actin 
(1:1000 dilution) was used as an internal loading control. Signals were quantified with the use of laser scanning densitometry and expressed 
as a percentage of the control. Values are mean ± SEM. Each quantified result was analyzed by two‑way ANOVA with a Bonferroni’s post hoc 
test. Differences between the two means were assessed by unpaired t‑test. The number of animals in each group was 6. *** P<0.005, ** P<0.01, 
* P<0.05.
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